Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. [electronic resource]
Producer: 20150831Description: 258-66 p. digitalISSN:- 1879-0712
- ATP Binding Cassette Transporter, Subfamily B -- antagonists & inhibitors
- ATP Binding Cassette Transporter, Subfamily G, Member 2
- ATP-Binding Cassette Transporters -- antagonists & inhibitors
- Acridines -- pharmacology
- Antineoplastic Agents -- chemistry
- Biological Transport -- drug effects
- Carcinoma, Renal Cell -- drug therapy
- Cell Line, Tumor
- Cell Survival -- drug effects
- Drug Resistance, Multiple -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- Drug Synergism
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Indoles -- agonists
- Kidney Neoplasms -- drug therapy
- Kinetics
- Membrane Transport Modulators -- pharmacology
- Neoplasm Proteins -- antagonists & inhibitors
- Protein Kinase Inhibitors -- chemistry
- Pyrroles -- agonists
- RNA, Messenger -- metabolism
- Sunitinib
- Tetrahydroisoquinolines -- pharmacology
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.